Researchers track how long men stay on prostate cancer drugs

NCT ID NCT07086651

Summary

This study looked back at real-world medical records to understand how long men with advanced prostate cancer that still responds to hormone therapy actually stay on two common medications: apalutamide and enzalutamide. Researchers analyzed data from about 1,300 men who were treated as part of their normal care, not in a controlled trial. The goal was to learn about real-life treatment patterns and how long patients continued these therapies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Pfizer, Inc

    New York, New York, 10001, United States

Conditions

Explore the condition pages connected to this study.